טוען...
P01.129 Cost-effectiveness of [18F] FET for therapy assessment of temozolomide for patients with glioblastoma in a Belgian healthcare setting
BACKGROUND: Temozolomide has been approved for the treatment of glioblastoma by the FDA in 2005 and became the standard of care very fast. However, more than 50% of the patients treated with temozolomide do not show any clinical response. MRI forms the main imaging modality to assess the therapy eff...
שמור ב:
| הוצא לאור ב: | Neuro Oncol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144657/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.171 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|